The brain-derived neurotropic growth factor (BDNF) gene has been linked to dementia, inflammation, and Apolipoprotein E (APOE) ɛ4 status. We used cerebrospinal fluid (CSF) amyloid-β (Aβ)42 and phosphorylated tau (p-tau) to investigate associations with BDNF polymorphisms and modifications by APOE ɛ4 or inflammation in a memory clinic population (n = 114; subjective cognitive decline, mild cognitive impairment, Alzheimer’s disease). We found distinct pathways to Alzheimer’s disease pathology: Val-Met displayed lower CSF-Aβ42 in APOE ɛ4+ carriers, independent of p-tau, while Val-Val displayed greater p-tau at higher IL-6 and sub-threshold Aβ42. This may contribute to resolving some inconsistencies in the BDNF literature and provide possible inroads to specific Aβ and tau interventions depending on BDNF polymorphism.
van den BoschKA, VerberkIMW, EbenauJL, vander Lee SJ, JansenIE, PrinsND, ScheltensP, TeunissenCE, Van der FlierWM (2021) BDNF-Met polymorphism and amyloid-beta in relation to cognitive decline in cognitively normal elderly: The SCIENCe project. Neurobiol Aging108, 146–154.
9.
Vilor-TejedorN, OpertoG, EvansTE, FalconC, Crous-BouM, MinguillónC, CacciagliaR, Milà-AlomàM, Grau-RiveraO, Suárez-CalvetM, Garrido-MartínD, MoránS, EstellerM, AdamsHH, MolinuevoJL, GuigóR, GispertJD (2020) Effect of BDNF Val66Met on hippocampal subfields volumes and compensatory interaction with APOE-ɛ4 in middle-age cognitively unimpaired individuals from the ALFA study. Brain Struct Funct225, 2331–2345.
DooleyLN, GanzPA, ColeSW, CrespiCM, BowerJE (2016) Val66Met BDNF polymorphism as a vulnerability factor for inflammation-associated depressive symptoms in women with breast cancer. J Affect Disord197, 43–50.
13.
RothaugM, Becker-PaulyC, Rose-JohnS (2016) The role of interleukin-6 signaling in nervous tissue. Biochim Biophys Acta1863, 1218–1227.
14.
BalschunD, WetzelW, Del ReyA, PitossiF, SchneiderH, ZuschratterW, BesedovskyHO (2004) Interleukin-6: A cytokine to forget. FASEB J18, 1788–1790.
15.
KummerKK, ZeidlerM, KalpachidouT, KressM (2021) Role of IL-6 in the regulation of neuronal development, survival and function. Cytokine144, 155582.
16.
SwardfagerW, LanctotK, RothenburgL, WongA, CappellJ, HerrmannN (2010) A meta-analysis of cytokines in Alzheimer’s disease. Biol Psychiatry68, 930–941.
17.
HagiharaK, NishikawaT, IsobeT, SongJ, SugamataY, YoshizakiK (2004) IL-6 plays a critical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system. Biochem Biophys Res Commun314, 363–369.
MurphyPG, BorthwickLA, AltaresM, GauldieJ, KaplanD, RichardsonPM (2000) Reciprocal actions of interleukin-6 and brain-derived neurotrophic factor on rat and mouse primary sensory neurons. Eur J Neurosci12, 1891–1899.
21.
VallièresL, CampbellIL, GageFH, SawchenkoPE (2002) Reduced hippocampal neurogenesis in adult transgenic mice with chronic astrocytic production of interleukin-6. J Neurosci22, 486–492.
22.
LiuCC, LiuCC, KanekiyoT, XuH, BuG (2013) Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy. Nat Rev Neurol9, 106–118.
23.
LynchJR, TangW, WangH, VitekMP, BennettER, SullivanPM, WarnerDS, LaskowitzDT (2003) APOE genotype and an ApoE-mimetic peptide modify the systemic and central nervous system inflammatory response. J Biol Chem278, 48529–48533.
24.
McCarreyAC, PachecoJ, CarlsonOD, EganJM, ThambisettyM, AnY, FerrucciL, ResnickSM (2014) Interleukin-6 is linked to longitudinal rates of cortical thinning in aging. Transl Neurosci5, 1–7.
25.
AlbertMS, DeKoskyST, DicksonD, DuboisB, FeldmanHH, FoxNC, GamstA, HoltzmanDM, JagustWJ, PetersenRC, SnyderPJ, CarrilloMC, ThiesB, PhelpsCH (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 270–279.
26.
GeerlingsMI, JonkerC, BouterLM, AderHJ, SchmandB (1999) Association between memory complaints and incident Alzheimer’s disease in elderly people with normal baseline cognition. Am J Psychiatry156, 531–537.
27.
EdwardsAW (2008) G. H. Hardy (1908) and Hardy–Weinberg equilibrium. Genetics179, 1143–1150.
28.
de JagerW, BourcierK, RijkersGT, PrakkenBJ, Seyfert-MargolisV (2009) Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays. BMC Im-munol10, 52.
29.
JohnsonPO, FayLC (1950) The Johnson-Neyman technique, its theory and application. Psychometrika15, 349–367.
30.
BauerDJ, CurranPJ (2005) Probing interactions in fixed and multilevel regression: Inferential and graphical techniques. Multivariate Behav Res40, 373–400.
31.
StonningtonCM, VelgosSN, ChenY, SyedS, HuentelmanM, ThiyyaguraP, LeeW, RichholtR, CaselliRJ, LockeDEC, LuB, ReimanEM, SuY, ChenK (2020) Interaction between BDNF Val66Met and APOE4 on biomarkers of Alzheimer’s disease and cognitive decline. J Alzheimers Dis78, 721–734.
32.
AdamczukK, WeerA-S, NelissenN, ChenK, SleegersK, BettensK, Van BroeckhovenC, VandenbulckeM, ThiyyaguraP, DupontP, LaereK, ReimanE, VandenbergheR (2013) Polymorphism of brain derived neurotrophic factor influences β amyloid load in cognitively intact apolipoprotein E ɛ4 carriers. Neuroimage Clin2, 512–520.
QuintanillaRA, OrellanaDI, González-BillaultC, MaccioniRB (2004) Interleukin-6 induces Alzheimer-type phosphorylation of tau protein by deregulating the cdk5/p35 pathway. Exp Cell Res295, 245–257.
37.
MarshSE, AbudEM, LakatosA, KarimzadehA, YeungST, DavtyanH, FoteGM, LauL, WeingerJG, LaneTE, InlayMA, PoonWW, Blurton-JonesM (2016) The adaptive immune system restrains Alzheimer’s disease pathogenesis by modulating microglial function. Proc Natl Acad Sci U S A113, E1316–E1325.
38.
IsingC, HenekaMT (2018) Functional and structural damage of neurons by innate immune mechanisms during neuro-degeneration. Cell Death Dis9, 120.
39.
PetryshenTL, SabetiPC, AldingerKA, FryB, FanJB, SchaffnerSF, WaggonerSG, TahlAR, SklarP (2010) Population genetic study of the brain-derived neurotrophic factor (BDNF) gene. Mol Psychiatry15, 810–815.
